Table 1.
Drug interaction analysis of cannabidiol (CBD) and the chemotherapeutic combinations in MCF7 breast cancer cells.
| Combo ID, Molar Ratio | CI Values at | CSS | S | ZIP | BLISS | LOEWE | HSA | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IC50 | IC75 | IC90 | IC95 | IC97 | |||||||
| CBD: Docetaxel | |||||||||||
| CDOC19, 18:1 | 1.23 | 1.35 | 1.64 | 2.07 | 2.60 | 35.5 | 0.33 | −11.81 | −19.12 | −6.84 | −15.76 |
| CDOC28, 40:1 | 0.96 | 1.14 | 1.62 | 2.32 | 3.18 | 54.6 | 18.07 | −10.9 | −13.6 | 14.29 | −9.42 |
| CDOC37, 68:1 | 0.70 | 0.91 | 1.46 | 2.27 | 3.27 | 41.33 | 3.96 | −9.74 | −11.35 | −8.14 | −7.08 |
| CDOC46, 106:1 | 0.49 | 0.70 | 1.23 | 2.04 | 3.03 | 49.82 | 13.09 | −3.4 | −5.61 | −2.36 | −1.38 |
| CDOC55, 159:1 | 0.45 | 0.70 | 1.35 | 2.33 | 3.54 | 52.65 | 14.33 | −3.34 | −4.58 | −2.05 | −0.8 |
| CDOC64, 238:1 | 0.50 | 0.86 | 1.80 | 3.20 | 4.94 | 51.66 | 12.22 | −3.04 | −4.2 | −1.74 | −0.29 |
| CDOC73, 371:1 | 0.38 | 0.72 | 1.61 | 2.95 | 4.61 | 52.44 | 13.36 | −2.36 | −3.69 | −1.35 | 0.07 |
| CDOC82, 636:1 | 0.42 | 0.61 | 1.00 | 1.46 | 1.93 | 56.64 | 20.16 | 1.94 | −0.1 | 1.86 | 3.4 |
| CDOC91, 1431:1 | 0.48 | 0.73 | 1.17 | 1.65 | 2.12 | 56.04 | 20.19 | 1.96 | −1.08 | 0.16 | 2.06 |
| CI to DC | - | - | - | - | - | 55.50 | 18.89 | −8.41 | −7.93 | −1.46 | −0.65 |
| Checkerboard | - | - | - | - | - | 72.91 | −11.77 | 1.76 | −5.07 | −4.17 | −0.66 |
|
Selected dose
(39.75, 0.5 µM) |
- | - | - | - | - | - | - | 28.12 | 21.45 | 24.27 | 46.02 |
| CBD: Doxorubicin | |||||||||||
| CDOX19, 18:1 | 1.17 | 1.16 | 1.15 | 1.14 | 1.14 | 64.78 | 46.12 | 6.07 | 4.52 | −5.24 | 1.62 |
| CDOX28, 40:1 | 1.12 | 1.11 | 1.10 | 1.10 | 1.09 | 66.93 | 46.23 | 3.32 | 1.97 | −9.04 | 0 |
| CDOX37, 68:1 | 1.07 | 1.06 | 1.05 | 1.05 | 1.05 | 66.94 | 43.69 | 0.18 | −1.53 | −10.92 | −2.66 |
| CDOX46, 106:1 | 1.42 | 1.41 | 1.40 | 1.39 | 1.38 | 65.5 | 42.45 | 0.61 | −1.64 | −11.27 | −2.78 |
| CDOX55, 159:1 | 1.34 | 1.33 | 1.32 | 1.31 | 1.31 | 24.4 | 1.7 | −13.69 | −46.05 | −55.66 | −48.18 |
| CDOX64, 238:1 | 1.27 | 1.26 | 1.25 | 1.25 | 1.25 | 69.85 | 45.41 | 4.15 | 2.24 | −6.37 | 0.99 |
| CDOX73, 371:1 | 1.20 | 1.19 | 1.19 | 1.18 | 1.18 | 73.33 | 48.85 | 6.67 | 5.38 | −2.87 | 4.15 |
| CDOX82, 636:1 | 1.13 | 1.13 | 1.12 | 1.12 | 1.12 | 75.33 | 52.37 | 10.19 | 9.06 | 0.67 | 7.38 |
| CDOX91, 1431:1 | 1.07 | 1.06 | 1.06 | 1.06 | 1.06 | 76.85 | 55.09 | 9.89 | 8.72 | −2.69 | 6.75 |
| CI to DC | - | - | - | - | - | 70.24 | 53.04 | 4.96 | 4.05 | −5.43 | 2.21 |
| Checkerboard | - | - | - | - | - | 54.90 | −5.31 | 1.04 | −1.05 | −9.15 | −4.31 |
|
Selected dose
(38.42, 0.2 µM) |
- | - | - | - | - | - | - | 32.52 | 25.65 | 15.16 | 31.53 |
| CBD: Paclitaxel | |||||||||||
| CPTX19, 18:1 | 1.50 | 1.61 | 1.89 | 2.35 | 2.95 | 35.94 | 0.09 | −12.32 | −20.86 | −20.59 | −19.3 |
| CPTX28, 40:1 | 0.91 | 1.04 | 1.40 | 2.00 | 2.78 | 42.63 | 5.16 | −7.42 | −12.28 | −11 | −9.74 |
| CPTX37, 68:1 | 0.70 | 0.85 | 1.31 | 2.05 | 3.03 | 40.73 | 2.11 | −8.38 | −11.49 | −10.07 | −8.88 |
| CPTX46, 106:1 | 0.48 | 0.63 | 1.09 | 1.83 | 2.82 | 50.48 | 12.66 | −2.18 | −5.93 | −4.42 | −3.42 |
| CPTX55, 159:1 | 0.37 | 0.54 | 1.04 | 1.85 | 2.93 | 55.54 | 16.97 | −0.14 | −3.26 | −2.93 | −1.55 |
| CPTX64, 238:1 | 0.37 | 0.59 | 1.24 | 2.32 | 3.75 | 51.98 | 11.68 | −1.04 | −4.26 | −3.37 | −1.96 |
| CPTX73, 371:1 | 0.34 | 0.61 | 1.41 | 2.73 | 4.49 | 52.76 | 12.71 | −0.76 | −3.19 | −2.35 | −1.01 |
| CPTX82, 636:1 * | 0.30 | 0.62 | 1.57 | 3.14 | 5.24 | 59.16 | 21.67 | 4.4 | 2.03 | 2.33 | 3.84 |
| CPTX91, 1431:1 * | 0.33 | 0.80 | 2.21 | 4.56 | 7.68 | 59.28 | 23.01 | 3.81 | 1.2 | 1.2 | 2.66 |
| CI to DC | - | - | - | - | - | 57.70 | 21.51 | −6.44 | −8.30 | −3.69 | −3.53 |
| Checkerboard | - | - | - | - | - | 53.78 | −31.41 | −5.35 | −10.85 | −7.90 | −6.63 |
|
Selected dose
(64.6, 0.1 µM) |
- | - | 0.68 | - | - | - | - | ~2.98 | ~−1.69 | ~6.1 | ~1.95 |
| CBD:SN38 | |||||||||||
| CSN19, 18:1 | 1.77 | 5.14 | 18.44 | 51.56 | 115.29 | 40.24 | 13.73 | −0.43 | −3.87 | −3 | −1.38 |
| CSN28, 40:1 | 0.65 | 0.86 | 1.49 | 2.52 | 3.84 | 48.26 | 20.38 | 1.13 | −0.58 | 1.23 | 2.95 |
| CSN37, 68:1 | 0.57 | 0.76 | 1.33 | 2.19 | 3.23 | 45.18 | 15.31 | −2.32 | −4.31 | −2.18 | −0.62 |
| CSN46, 106:1 * | 0.47 | 0.59 | 0.95 | 1.44 | 1.98 | 50.63 | 21.35 | 1.96 | 0.13 | 2.04 | 3.69 |
| CSN55, 159:1 | 0.47 | 0.60 | 0.94 | 1.37 | 1.82 | 50.13 | 19.75 | 1.08 | −0.83 | −0.05 | 1.7 |
| CSN64, 238:1 | 0.45 | 0.60 | 0.97 | 1.40 | 1.85 | 49.6 | 18.07 | 0.23 | −1.72 | 0.05 | 1.64 |
| CSN73, 371:1 ** | 0.81 | 0.66 | 0.61 | 0.60 | 0.59 | 52.98 | 21.84 | 1.83 | 0.38 | 1.99 | 3.57 |
| CSN82, 636:1 ** | 0.81 | 0.71 | 0.68 | 0.67 | 0.67 | 59.38 | 29.68 | 5.05 | 3.67 | 4.45 | 6.4 |
| CSN91, 1431:1 ** | 0.92 | 0.93 | 0.91 | 0.91 | 0.90 | 58.73 | 29.9 | 3.43 | 2.21 | 2.79 | 4.66 |
| CI to DC | - | - | - | - | - | 48.39 | 23.86 | 2.37 | 1.35 | 3.58 | 4.46 |
| Checkerboard | - | - | - | - | - | 75.94 | 1.36 | 0.31 | −3.24 | −3.09 | −0.08 |
|
Selected dose
(42.45, 0.11 µM) |
- | 0.66 | - | - | - | - | - | 14.55 | 23.86 | 31.38 | 33.57 |
| CBD: Vinorelbine | |||||||||||
| CVIN19, 18:1 | 1.30 | 1.39 | 1.64 | 2.02 | 2.53 | 31.94 | −1.9 | −9.19 | −16.9 | −16.72 | −15.15 |
| CVIN28, 40:1 | 1.03 | 1.18 | 1.58 | 2.25 | 3.12 | 37.98 | 2.98 | −8.44 | −12.37 | −12.2 | −10.12 |
| CVIN37, 68:1 | 0.71 | 0.86 | 1.30 | 2.02 | 2.96 | 41.71 | 5.92 | −6.9 | −8.99 | −7.59 | −5.91 |
| CVIN46, 106:1 | 0.56 | 0.74 | 1.26 | 2.12 | 3.25 | 44.84 | 9.79 | −4.31 | −6.29 | −5.35 | −3.24 |
| CVIN55, 159:1 | 0.46 | 0.67 | 1.27 | 2.26 | 3.58 | 50.93 | 14.65 | −1.54 | −3.63 | −3.13 | −1.06 |
| CVIN64, 238:1 | 0.45 | 0.72 | 1.52 | 2.84 | 4.58 | 49.75 | 12.98 | −2.21 | −5.08 | −3.64 | −1.84 |
| CVIN73, 371:1 | 0.33 | 0.59 | 1.36 | 2.63 | 4.32 | 52.5 | 16.13 | 0.16 | -2.16 | −1.01 | 1.06 |
| CVIN82, 636:1 * | 0.32 | 0.65 | 1.65 | 3.30 | 5.49 | 55.57 | 21.19 | 3.31 | 1.6 | 1.94 | 4.38 |
| CVIN91, 1431:1 ** | 0.73 | 0.60 | 0.56 | 0.55 | 0.55 | 56.32 | 25.34 | 5.55 | 3.36 | 2.56 | 5.09 |
| CI to DC | - | - | - | - | - | 57.45 | 23.54 | −5.89 | −6.49 | −1.64 | −0.70 |
| Checkerboard | - | - | - | - | - | 56.45 | −30.43 | −1.79 | −6.39 | −4.94 | −4.07 |
|
Selected dose
(42.4, 0.1 µM) |
- | ~0.62- | - | - | - | - | - | 18.29 | 28.44 | 43.26 | 48.43 |
CI = combination index; CI to DC = all combined responses from CI model combinations were analysed via DrugComb server; CSS = combination sensitivity score; IC = inhibitory concentration killing the corresponding percentage of MCF7 cells; HSA = highest single agent model; ZIP = zero interaction potency model; ** = synergistic combinations in all models and inhibitory concentrations; * = synergistic combinations in all models and most effective doses; ~ = approximate score considered. Potential synergistic combinations with CI < 0.7 or synergy score > 1.5 in Loewe, HSA, ZIP, and Bliss models, or > 20 in the S model, are bold formatted. Potential effective combinations (CSS > 55) are bold formatted. Synergy metrics listed for the selected doses are derived from CI to DC.